Cardiovascular and Renal Drugs Advisory Committee
Meeting materials from 2019 and older are archived and can be accessed using the following hyperlinks: 2020, 2019, 2015, 2014, 2013, 2012, 2011, 2010, 2009, materials prior to 2009
The Committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cardiovascular and renal disorders and makes appropriate recommendations to the Commissioner of Food and Drugs.
The Committee shall consist of a core of 11 voting members including the Chair. Members and the Chair are selected by the Commissioner or designee from among authorities knowledgeable in the fields of cardiology, hypertension, arrhythmia, angina, congestive heart failure, diuresis, and biostatistics. The core of voting members may include one technically qualified member, selected by the Commissioner or designee, who is identified with consumer interests and is recommended by either a consortium of consumer-oriented organizations or other interested persons. In addition to the voting members, the Committee may include one non-voting member who is identified with industry interests.
Yvette Waples, PharmD
Acting Designated Federal Officer (DFO)
Division of Advisory Committee and Consultant Management
Office of Executive Programs
FDA Advisory Committee Information Line
(301) 443-0572 (local number)
Please call the Information Line for up-to-date information on meetings.
- FDA Advisory Committee Information Line
- (301-443-0572 in the Washington DC area)
Please call the Information Line for up-to-date information on this meeting.